Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A inact mut |
| Therapy | Tazemetostat |
| Indication/Tumor Type | urinary bladder cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A inact mut | urinary bladder cancer | sensitive | Tazemetostat | Preclinical - Cell culture | Actionable | In a preclinical study, Tazverik (tazemetostat) inhibited viability of bladder cancer cell lines harboring ARID1A inactivating mutations in culture (PMID: 35852858). | 35852858 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35852858) | ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. | Full reference... |